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Background: Hyaluronan accumulation correlates with the degree of malignancy in many solid tumor types,
including malignant endometrial carcinomas. To elucidate the mechanism of hyaluronan accumulation, we
examined the expression levels of the hyaluronan synthases (HAS1, HAS2 and HAS3) and hyaluronidases (HYAL1 and
HYAL2), and correlated them with hyaluronan content and HAS1-3 immunoreactivity.
Methods: A total of 35 endometrial tissue biopsies from 35 patients, including proliferative and secretory
endometrium (n = 10), post-menopausal proliferative endometrium (n = 5), complex atypical hyperplasia (n = 4),
grade 1 (n = 8) and grade 2 + 3 (n = 8) endometrioid adenocarcinomas were divided for gene expression by real-
time RT-PCR, and paraffin embedded blocks for hyaluronan and HAS1-3 cytochemistry.
Results: The mRNA levels of HAS1-3 were not consistently changed, while the immunoreactivity of all HAS proteins
was increased in the cancer epithelium. Interestingly, HAS3 mRNA, but not HAS3 immunoreactivity, was increased
in post-menopausal endometrium compared to normal endometrium (p = 0.003). The median of HYAL1 mRNA was
10-fold and 15-fold lower in both grade 1 and grade 2+3 endometrioid endometrial cancers, as compared to
normal endometrium (p = 0.004-0.006), and post-menopausal endometrium (p = 0.002), respectively. HYAL2 mRNA
was also reduced in cancer (p = 0.02) and correlated with HYAL1 (r = 0.8, p = 0.0001). There was an inverse
correlation between HYAL1 mRNA and the epithelial hyaluronan staining intensity (r = -0.6; P = 0.001).
Conclusion: The results indicated that HYAL1 and HYAL2 were coexpressed and significantly downregulated in
endometrioid endometrial cancer and correlated with the accumulation of hyaluronan. While immunoreactivity for
HASs increased in the cancer cells, tumor mRNA levels for HASs were not changed, suggesting that reduced
turnover of HAS protein may also have contributed to the accumulation of hyaluronan.
Background
Cancer of the endometrium is the most common malig-
nant tumor of the female genital tract and it typically
affects postmenopausal women [1,2] The prognosis of
endometrial cancer is generally good, since the age-
adjusted 5-year overall survival is 82% [3]. Although
most patients are diagnosed at an early stage, i.e. disease
confined to the uterus, still 20% of the cancers recur
after primary treatment. Adjuvant treatment does not
prolong the overall survival, maybe because of inade-
quate patient selection. Therefore, new prognostic mar-
kers are needed. Molecular markers in endometrial
cancer are still rather poorly defined [4].
It has been commonly recognized that development of
human neoplasia is accompanied by changes in the extra-
cellular matrix (ECM) which is particularly important in
regulating tumor dissemination [5]. The glycosaminogly-
can hyaluronic acid/hyaluronan (HA) is a ubiquitous
component of the extracellular matrix (ECM).
Hyaluronan is an independent, unfavorable prognos-
tic factor in another gynaecological malignancy, epithe-
lial ovarian cancer [6], and a number of other
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are both involved in the development and progression
of endometrial cancer [9].
Hyaluronan can be produced in mammals by three
hyaluronan synthase isoenzymes: HAS1, HAS2 and
HAS3 [10]. HAS mRNA levels often correspond to the
rate of hyaluronan synthesis, and are known to influence
the content of hyaluronan in transplanted tumors [11].
Therefore, upregulation of HAS expression can contri-
bute to the hyaluronan accumulation in tissues, and
promote tumor growth and metastasis in experimental
animals, in particular when coexpressed with hyaluroni-
dase [12,13].
The catabolism of hyaluronan is more complex pro-
cess [14]. Hyaluronan in the extracellular matrix can be
partially fragmented by hyaluronidase activity or oxygen
free radicals, and diffuse away through lymph. Alterna-
tively, hyaluronan can be taken up by adjacent cells and
be subject to lysosomal degradation in the tissue of ori-
gin [15]. The rate of hyaluronan catabolism may there-
fore be contributed by the formation of oxygen free
radicals, access to lymph, local uptake by cells, and
hyaluronidases.
There are 6 hyaluronidases in the human genome, two
of them (HYAL1 and HYAL2) are ubiquitous and char-
acterized at protein level [16]. HYAL1 and HYAL2 have
been shown to inhibit tumor growth in vivo,a n di th a s
been suggested that these two genes have major roles in
the microenvironment of tumor cells [17]. Recent find-
ings have suggested that depending on its concentration,
HYAL1 can function either as a tumor promoter or as a
suppressor [18].
The major transcript of HYAL3 is enzymatically inactive
a n da p p e a r st oh a v eo n l yas u p p o r t i v er o l ei nHYAL 1
expression [19]. HYAL 3 knockout mice do not display
any evidence of hyaluronan accumulation [20]. Very little
is known about HYAL4, but its expression is limited, and
it might be a chondroitinase rather than hyaluronidase
[16,21]. The expression of the SPAM1 gene-encoded
PH20 hyaluronidase is almost exclusively detected in testis
and sperm, and shows activity in higher pH.
In an invasive bladder cancer cell line, blocking of
HYAL1 expression decreases tumor growth, inhibits
tumor infiltration and decreases microvessel density [22].
Increased hyaluronidase expression has also been reported
in prostate [18] and colon cancer [14], and in breast
tumor metastases [23]. In contrast, recent findings have
shown that the expression of HYAL1 and HYAL2 genes is
significantly decreased in lung and kidney cancer samples
[17]. Also experimental overexpression of HYAL1 in a rat
colon carcinoma cell line inhibits tumor growth and gen-
erates necrotic tumors [11].
We have found that the median concentration of
hyaluronan is increased in malignant ovarian tumors
without hyaluronidase activation [24]. In further studies
we have shown that significantly decreased HYAL1
expression correlates with decreased hyaluronidase
activity and elevated hyaluronan content of the tumors,
while HAS expression was not as consistently associated
to the accumulation of hyaluronan [25].
In this study we found that in the most common
gynaecological malignancy, endometrial cancer, the
accumulation of hyaluronan is also associated with
decreased expression of hyaluronidase genes. Blocking
the accumulation of hyaluronan might offer a new way
of fighting against these diseases
Methods
Patients
A total of 35 endometrial tissue specimens from 35
patients were divided into 5 groups: proliferative and
secretory endometrium (n = 10), post-menopausal pro-
liferative endometrium (n = 5), complex atypical hyper-
plasia (n = 4), grade 1 (n = 8) and grade 2+3 (n = 8)
endometrioid adenocarcinomas (Table 1). The normal
endometrium tissue specimens were obtained from hys-
terectomies for nonmalignant diseases (e.g. leiomyoma
or prolapse of uterus). The malignant tumors of endo-
metrium were staged according to FIGO. The ethical
committee of the Kuopio University Hospital has
approved the study protocol and patients signed the
informed consent.
Histology
Histological typing and grading were done according to
the WHO classification [26,27]. Grade 2 and 3 cancers
were combined into one subgroup.
Tissue samples
The tissue specimens collected in the operation room
were prepared and evaluated by an experienced pathol-
ogist (KH). All the samples were collected and handled
identically. Aliquots of the tissues were 1) placed in
RNAlater® (Ambion, Austin, TX) for mRNA analyses;
2) fixed in 10% buffered formalin and embedded in
paraffin.
RNA Extraction and cDNA Preparation
Samples were stored at -80°C until RNA preparation. The
samples were frozen by liquid nitrogen and pulverized
under pressure using a stainless steel cylinder and a pis-
ton. Total RNA was isolated using Trizol® Reagent (Invi-
trogen) according to manufacturer’s protocol, quantified
spectrophotometrically and its integrity confirmed by
agarose electrophoresis, based on the appearance of the
18S and 28S RNA bands. First strand cDNA was synthe-
s i z e df r o m2 . 5μg of total RNA using High-Capacity
cDNA Archive kit (Applied Biosystems, Foster City, CA)
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of 50 μl.
Quantitative real-time RT-PCR
R e a l - t i m eg e n ee x p r e s s i o na nalysis of all target genes
(HYAL1, HYAL2, HAS1-3) was performed using TaqMan®
Gene Expression Assays (Applied Biosystems) according
to manufacturer’s instructions and as described previously
[25]. The assay numbers for these genes were as follows:
Hs00201046_m1 (HYAL1); Hs00186841_m1 (HYAL2);
Hs00758053_m1 (HAS1); Hs00193435_m1 (HAS2);
Hs00193436_m1 (HAS3); Hs99999909_m1 (HPRT).
The HPRT1 gene we used for normalization was an
accurate reference for the quantitative gene expression
assays in clinical tumor samples [28]. Relative gene
expression values were calculated as the ratio between
the target gene and HPRT1, obtained for each sample
from the standard curves.
Staining of HASs
The HAS immunostainings were performed as described
previously [25]. Shortly, antigen retrieval was performed
for HAS1-3 staining by boiling for 3 × 5 min in a citrate
buffer. Thereafter sections were treated for 5 min with
1% H2O2 to block endogenous peroxidise activity and
incubated in 1% bovine serum albumin (BSA) in PBS for
30 min to block nonspecific binding. The sections were
incubated overnight at 4°C with polyclonal antibodies for
HAS1 (2 μg/ml, sc-34021, Santa Cruz Biotechnology,
i n c . ,S a n t aC r u z ,C A ) ,H A S 2( 2μg/ml, sc-34067, Santa
Cruz) or HAS3 (2 μg/ml sc-34204, Santa Cruz), diluted
in 1% BSA. Sections were incubated for 1 hour with bio-
tinylated antigoat antibody (1:1000, Vector Laboratories).
The bound antibodies were visualized with the avidin-
biotin peroxidase method (1:200, Vectastain Kit, Vector
Laboratories), yielding a brown reaction product. The
sections were counterstained with Mayer’s hematoxylin.
The staining intensity of HAS1, HAS2 and HAS3 was
graded into three categories in the epithelium: negative
(n.d.), weak and moderate, and into two categories in the
stroma: negative (n.d.) or weak. The percentage of posi-
tive area for each HAS was estimated both in stroma and
epithelium.
Staining of Hyaluronan
Deparaffinized 5-μmt i s s u es e c t i o n sw e r es t a i n e df o r
hyaluronan with our own preparation of biotinylated
hyaluronan-binding complex (bHABC) as described in
detail previously [24]. All samples were scored by an
observer unaware of the clinical data (M.A.). The inten-
sity of hyaluronan positivity in epithelium and in stroma
was graded into three categories: 1 (weak); 2 (moderate);
and 3 (strong) and the area percentage of the strongest
hyaluronan expression in the whole tumor section was
evaluated separately in epithelium and stroma.
Statistical methods
Statistical analyses were carried out using SPSS 16.0 for
Windows (SPSS, Chicago, IL). Differences between the
patient groups were first analysed by using a non-para-
metric Kruskal-Wallis test, and when found significant a
non-parametric Mann - Whitney U-test was used for
further comparisons between the patient groups. Correla-
tions between gene expression data and hyaluronan
staining and immunostaining scores were analysed by
using the Spearman’s correlation test. A Chi-square test
was used to analyse the association of hyaluronan stain-
ing and immunostaining scores. We considered p-value ≤
0.01 as statistically significant.
Results
Expression of HAS1, HAS2 and HAS3
mRNA from normal endometrium and different tissue
lesions were analyzed by real-time RT-PCR for the hya-
luronan synthases HAS1, HAS2,a n dHAS3 (figure 1).
Transcripts of HAS1 were detected at such a low level
that reliable quantitation was not consistently possible.
Expression of HAS2 was not significantly changed in
Table 1 Clinicopathological data of the tissue samples
Tissue type Histology No. Patients Age at diagnosis
† FIGO stage
IB IC II
Normal endometrium Proliferating 4 42 (42-45)
Secreting 6 48 (41-52)
Postmenopausal Proliferating 5 69 (57-75)
Hyperplastic endometrium Complex atypical 4 52 (45-68)
Malignant endometrium
Endometrioid adenocarcinoma Grade I 8 66 (46-76) 4 3 1
Grade II 4 70 (63-81) 2 1 1
Grade III 4 62 (41-81) 1 2 2
All patients 35
† median (range).
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Page 3 of 10Figure 1 HAS 2-3 mRNA expression in human endometrium and its lesions. Relative mRNA levels of A) HAS2 and B) HAS3 in different
tissues. The boxes show the ranges between 25th and 75th percentiles, with a horizontal line at the median value. The whiskers extend to the
10th and 90th percentiles. The open circles represent the outlier values. NE = normal pre-menopausal endometrium, PME = post-menopausal
proliferative endometrium, CAH = complex atypical hyperplasia, G1 = grade 1 endometrioid endometrial adenocarcinoma, G2 + 3 = grade 2 + 3
endometrioid endometrial adenocarcinoma.
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tissues as compared to normal endometrium (figure 1A).
On the other hand HAS3 expression was increased over
4-fold in post-menopausal endometrium (p = 0.003)
compared to pre-menopausal endometrium. We also
noticed that HAS3 expression was also elevated (1.5-fold
increase) in grade 1 malignant tumors compared to nor-
mal endometrium, this finding being borderline signifi-
cant (p = 0.033) (figure 1B).
Expression of HYAL1 and HYAL2
Since the two ubiquitous hyaluronidases, HYAL1 and
HYAL2, were likely to account for most or all of the hya-
luronidase activity, we quantified their mRNA levels by
real-time RT-PCR (figure 2). There was a significant
decline in HYAL1 expression from normal endometrium
to the cancers (Kruskal Wallis p = 0.002). A 10-fold higher
expression of median HYAL1 mRNA expression was
found in normal endometrium as compared to both grade
1 and grade 2 + 3 malignant tumors, and over 15-fold
higher values were seen in normal post-menopausal endo-
metrium (figure 2A). Similar trend was noticed between
HYAL2 expression in grade 1 and grade 2 + 3 cancers
compared to normal endometrium, this difference being
borderline significant (figure 2B). There was also a strong
and statistically significant correlation between HYAL1
and HYAL2 expressions (r = 0.8; p < 0.0001)
HAS immunostainings
The epithelial intensities of HAS1 (figure 3A,B), HAS2
(figure 3C,D) and HAS3 (figure 3E,F) immunostainings
were significantly stronger in endometrial tumors com-
pared to normal endometrium (p = 0.001, p = 0.004
and p = 0.003, respectively) (table 2). However, the
staining intensities did not correlate with tumor grade.
Epithelial hyaluronan staining intensity was associated
with HAS2 epithelial staining intensity (p = 0.009). No
significant correlations were found between the mRNA
levels and immunohistochemical protein scores of
HAS1-3. On the other hand, an inverse correlation of
HYAL1 expression with HAS3 epithelial staining inten-
sity was found (r = -0.5, p = 0.004).
Hyaluronan content
The level of hyaluronan accumulation in the present set
of lesions was scored from tissue sections using a bioti-
nylated probe that specifically binds hyaluronan [6] (fig-
ure 3G,H). This histological assay closely correlates with
biochemical quantitation of hyaluronan [24]. Epithelial
and also stromal hyaluronan intensity score was signifi-
cantly elevated (p = 0.0001 and p = 0.006 respectively)
in the endometrioid endometrial tumors compared to
normal endometrium (table 3).
Relationship between hyaluronan accumulation and HAS
and HYAL mRNA levels
No significant correlations were found between the level
of HAS2 or HAS3 mRNA and the hyaluronan content.
Instead, HYAL1 transcript levels showed a significant
inverse correlation with epithelial (r = -0.6, p = 0.001)
and stromal hyaluronan staining score (r = -0.4
p = 0.01). HYAL2 transcript levels also correlated with
epithelial hyaluronan staining score (r = -0.4 p = 0.01).
Discussion
Hyaluronan synthase and hyaluronidase mRNA levels
were quantitated for the first time in a set of sample
groups from normal endometrium, post-menopausal
endometrium, endometrial hyperplasia and endome-
trioid endometrial tumors.
HAS mRNA expression and immunohistochemistry in
endometrioid endometrial cancer
Except for a trend of HAS3 increase in grade 1 carcino-
mas, we did not find a clear pattern of increased HAS1-
3 mRNA in endometrial cancer, as compared to normal
endometrium. This finding is somewhat similar to the
enhanced HAS3 mRNA level observed in benign, but
not in malignant ovarian tumors [25]. On the other
hand, HAS3 mRNA was increased in proliferating post-
menopausal endometrium, and has been suggested to
promote the growth of bladder carcinoma cells [29].
Nevertheless, our results suggested that transcriptional
upregulation of HAS gene expression was not the main
contributor to the increased hyaluronan content of
these tumors.
Despite minor changes in mRNAs, the immunoreac-
tivity for all HASs was stronger in cancer cells com-
pared to normal endometrium, although the density of
the stainings did not significantly correlate with tumor
grade. A similar discordance between the levels of HAS
mRNA and HAS immunoreactivity was earlier found in
ovarian cancer [25]. Curiously, the statistical significance
for the cancer-associated increase of HAS immunoreac-
tivity was strongest for HAS1 although real-time RT-
PCR suggested very low transcription of this gene. As in
the present study, Yabushita et al. [30] found that HAS1
immunoreactivity showed a strong association with
endometrial cancer.
HAS2 is the only HAS gene which deletion causes a
clear (lethal) phenotype [31], and it has been suggested
to be most important for hyaluronan synthesis. In line
with this idea, the immunohistochemical signal of
epithelial HAS2 correlated with the staining score of
epithelial HA.
Since the HAS gene expressions in tumor tissues
poorly correlated with the content of the respective
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Page 5 of 10Figure 2 HYAL 1-2 mRNA expression in human endometrium and its lesions.R e l a t i v em R N Al e v e l so fA )HYAL1 and B) HYAL2 in different
tissues. The boxes show the ranges between 25th and 75th percentiles, with a horizontal line at the median value. The whiskers extend to the
10th and 90th percentiles. NE = normal pre-menopausal endometrium, PME = post-menopausal proliferative endometrium, CAH = complex
atypical hyperplasia, G1 = grade 1 endometrioid endometrial adenocarcinoma, G2 + 3 = grade 2 + 3 endometrioid endometrial
adenocarcinoma.
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Page 6 of 10Figure 3 HAS 1-3 immunoreactivity and HA-staining in normal and neoplastic human endometrium. Immunostaining of HAS1 (A, B),
HAS2 (C, D), HAS3 (E, F) and HA (G, H) in normal human endometrium (A, C, E, G) and in grade 2 endometrioid endometrial carcinoma tissue
sections (B, D, F, H). The brown color (DAB) indicates HAS (A-F) or HA (G, H), and blue color (haematoxylin) indicates nuclei. A-F: 200× original
magnification. G, H: 100× original magnification.
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the turnover of the HAS proteins should become slower
in cancer cells. The time of functional work life of the
HAS proteins in tissues was not known, but if extended,
it may have had a major influence on hyaluronan
synthesis.
Decreased expression of HYAL1 and HYAL2 mRNA and
association to hyaluronan accumulation
The present findings of decreased HYAL1 and HYAL2
mRNA in endometrial cancer are consistent with the
results we have recently shown in ovarian cancer [25].
Our findings are also similar to those of lung and kidney
cancer samples in which a major down-regulation of
HYAL1 and HYAL2 genes has been shown [17]. Our
findings in endometrial and ovarian cancer are in con-
trast to reports on prostate and bladder tumors in
which increased HYAL1 protein and mRNA expression
is associated with advanced disease and unfavorable
prognosis [32,18,22]. One hypothesis to solve this con-
tradiction between different types of cancers is that
malignancies arising from different cell types use differ-
ent strategies to progress and evolve. The relative
importance of the opposite roles of hyaluronidase func-
tion in a particular type of cancer probably determines
the outcome. The expression level is also important
since HYAL1 can either promote or suppress malignant
growth in a single cell type, depending on the resulting
enzyme activity [18].
HYAL1, a tumor suppressor
HYAL1 and HYAL2 genes are located in 3p21.3 chromo-
some region, where allelic imbalance is frequent [33,14].
In the present study we noticed a strong correlation
between HYAL1 and HYAL2 mRNA expression. It is pos-
sible that in endometrial cancer the HYAL mRNA
expression depends on the status of the chromosome
3p21.3 locus, and the decreased expression of HYAL1 and
HYAL2 may be explained by concomitant deletions of
t h e s ec l o s e l ym a p p e dg e n e s .O n et h e o r yt oe x p l a i nw h y
decreased expression of hyaluronidase genes could lead to
the development of cancer is HYAL1 and its role in apop-
tosis. High HYAL1 activity can result in apoptosis by
increasing the expression of WOX1 (WW domain-con-
taining oxidoreductase, WWOX) [22]. WOX1 causes
mitochondrial permeabilization and is an essential partner
of p53 in cell death [34]. Hyaluronidase can also cause
apoptosis by inducing NAD+-linked 15-hydroxyprosta-
glandin dehydrogenase (15-PDGH), an enzyme that
degrades prostaglandins and promotes apoptosis in lung
carcinoma cells [35]. Furthermore, the high molecular
mass hyaluronan that occupies cell surface CD44 recep-
tors maintains p-Akt and PI3K dependent signals that pre-
vent cancer cell apoptosis, while hyaluronidase, and the
oligosaccharides created by hyaluronidase, block these cell
survival signals [36]. It has also been recently demon-
strated that ectopic expression of all three different
somatic hyaluronidases (HYAL1, HYAL2 and HYAL3)
induce granulosa cell apoptosis [37].
Conclusion
The results indicated that HYAL1 and HYAL2 were
coexpressed and significantly downregulated in endome-
trioid endometrial cancer and correlated with the accu-
mulation of hyaluronan. The expression of HAS1-3
mRNA is not elevated in endometrioid endometrial can-
cer while their immunoreactivity is elevated, suggesting
cancer-associated changes in HAS protein turnover.
Abbrevations
HYAL: hyaluronidase; HAS: hyaluronan synthase; FIGO:
International Federation of Gynecologists and Obstetrics.






n.d. weak moderate strong n.d. weak moderate strong
Normal n = 9 9 0 0 0 0 0 9 (60%; 10-90%) 0
Proliferating pm
† n = 5 5 0 0 0 0 3 1 (30%) 1 (100%)
Hyperplasia
# n = 2 0 1 (5%) 1 (40%) 0 0 1 (40%) 0 1 (30%)
Grade 1
‡ n = 8 1 0 5 (2-5%) 2 (5-10%) 0 0 5 (70%; 20-80%) 3 (80%; 50-100%)
Grade 2+3
‡ n = 8 1 0 4 (15%; 10-60%) 3 (30%; 20-30%) 0 0 2 (50-80%) 6 (80%; 20-90%)
* num. of samples with % of positive cells (% in median; range when necessary).
n.d. = not detected/negative.
# complex atypical hyperplasia.
†pm = post-menopausal.
‡ endometrioid endometrial adenocarcinoma.
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